Abstract: Use of hexahydro-dibenzo[a,g]quinolizine compounds as shown in formula(I) in preparing a medicine for treating and/or preventing benign prostate hyperplasia diseases.

Abstract: The object of the present invention is to provide a process for producing ?-fluoroacrylic acid ester at a high starting material conversion, high selectivity, and high yield. The present invention provides a process for producing the compound represented by the formula (1) wherein R represents alkyl optionally substituted with one or more fluorine atoms, the process comprising step A of reacting a compound represented by the formula (2) wherein X represents a bromine atom or a chlorine atom with an alcohol represented by the formula (3) wherein the symbol is as defined above, and carbon monoxide in the presence of a transition metal catalyst and a base to thereby obtain the compound represented by the formula (1).

Abstract: This invention is related to compounds and/or compositions useful against pathogens affecting meats, plants, or plant parts. In one embodiment, the provided compounds are products of certain oxaborole moieties. In a further embodiment, the compound comprises certain halogen substitutions on the boron atom. Delivery systems are also provided to take advantage of their fungicidal activity and/or volatile nature of these compounds and/or compositions. In another embodiment, the compounds disclosed have herbicidal activity.

Abstract: A process for conducting equilibrium-limited chemical reactions that produce water as a reaction product. Specifically, a process that uses a reactive chromatography unit (RCU) to improve the efficiency of equilibrium-limited reactions, such as a process for reacting glycol ether (GE) and carboxylic acid (CA) to form water and glycol ether ester (GEE). The process includes supplying GE and CA to the RCU, where one of either the CA or the GE is in a stoichiometric deficit relative to the other reactant. The reactant in the stoichiometric deficit reacts in the presence of the catalyst in the RCU to form a mixture of GEE and water. A raffinate is separated from the mixture using the separation media of the RCU contains at least the GEE. An extract separated from the mixture using the separation media of the RCU contains at least the water.

Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.

Abstract: This specification discloses an operational continuous process to convert lignin as found in ligno-cellulosic biomass before or after converting at least some of the carbohydrates. The continuous process has been demonstrated to create a slurry comprised of lignin, raise the slurry comprised of lignin to ultra-high pressure, deoxygenate the lignin in a lignin conversion reactor over a catalyst which is not a fixed bed without producing char. The conversion products of the carbohydrates or lignin can be further processed into polyester intermediates for use in polyester preforms and bottles.

Abstract: The present invention relates to a method for preparing enantiomerically pure compounds 1a and 1b of the following formula 1 from racemic compound 1 of the following formula 1. [formula 1] The compounds 1a and 1b of the above formula 1 respectively are important intermediates for a process for preparing the respective compounds 2a and 2b of the following formula 2, which are 2,2?-binaphthol-3-aldehyde derivatives. The following compounds 2a and 2b are useful for preparing enantiomerically pure amino acids. The present invention provides a method for preparing the above compounds 1a and 1b very conveniently and economically, and suitably for mass production.

Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

Abstract: This specification discloses a process to convert a converted lignin feedstream to an aromatic composition comprised of aromatic compounds. The process follows the steps of exposing the converted lignin feedstream to at least one catalyst in the presence of donated hydrogen atoms at an exposure temperature greater than 190° C. for a time of at least thirty minutes. The donated hydrogen atoms are donated from at least one hydrogen donating compound during exposure of the converted lignin feedstream to the at least one catalyst at the exposure temperature. The resulting products are comprised largely of aromatics.

Abstract: A pharmaceutical combination comprising (a) a B-Raf inhibitor and (b) a histone deacetylase inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract: The present invention relates to methods of treating a disease related to cell hyper-proliferation via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently.

Abstract: The present invention relates to novel compounds that are useful as ligands in organometallic dyes. More particularly, the invention relates to dyes comprising the compounds, said dyes being sensitizing dyes useful in solar cell technology. According to an embodiment, the present invention discloses new ruthenium dyes and their application in dye-sensitized solar cells (DSC). The referred ruthenium dyes with new structural features can be easily synthesized, show more than 85% light-to-electricity conversion efficiency and a higher than 9% cell efficiency.

Abstract: The invention relates to medicine and pharmacology, more particularly to drugs, and even more particularly to pharmaceutical compositions for treating gastroesophageal reflux disease (GERD). The pharmaceutical composition for treating GERD contains at least one proton pump inhibitor (PPI) and at least one prebiotic. Also claimed is a method for treating gastroesophageal reflux disease in which it is not necessary to eradicate the presence of H. pylori in order to prevent the risks associated with the translocation of said bacteria from the antrum to the body of the stomach. The composition provides for prevention of the translocation of H. pylori by means of the colonization of the antrum by lactobacilli and the concurrent inhibition of H. pylori during PPI therapy. This makes it possible to dispense with the need to detect the bacteria and carry out a course of eradication therapy. The safety of long-term PPI therapy is increased.

Abstract: The present invention provides a method for preparing a sample characterized by binding a substance A containing a hydrazide group to a sugar chain and/or a sugar derivative via hydrazone formation between the hydrazide group of the substance A and the reducing end of the sugar chain and/or the sugar derivative thereby to enable the separation and purification of the sugar chain and/or the sugar derivative for an analytical sample from a biological sample containing the sugar chain and/or the sugar derivative by a simple operation.

Abstract: Target compounds are synthesized simply, efficiently and selectively. More specifically, provided are a method for producing (2,4,4-trimethyl-1-cyclohexene)carbaldehyde, comprising the steps of: reacting the carbonyl group of 2,4,4-trimethyl-2-cyclohexenone (1) to obtain a 2,4,4-trimethyl-2-cyclohexenylidenemethyl ether compound (2) and hydrolyzing Compound (2) to obtain the (2,4,4-trimethyl-1-cyclohexene)carbaldehyde (3); a method for producing (2,4,4-trimethyl-1-cyclohexene)methanol, comprising a step of reducing Compound (3) to obtain the (2,4,4-trimethyl-1-cyclohexene)methanol (4); and a method for producing a (2,4,4-trimethyl-1-cyclohexenyl)methyl ester compound, comprising a step of esterifying Compound (4) to obtain the (2,4,4-trimethyl-1-cyclohexenyl)methyl ester compound (5).

Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.

Abstract: Disclosed are a method for preparing 1-palmitoyl-3-acetylglycerol in high purity and high yield without a purification process using a column chromatography, and a method for preparing 1-palmitoyl-2-linoleoyl-3-acetylglycerol in high purity and high yield using the same as a key intermediate. The method for preparing 1-palmitoyl-3-acetyl glycerol comprises the steps of: forming a reaction mixture including 1-palmitoyl-3-acetyl glycerol of the Formula 1 in the specification by reacting 1-palmitoylglycerol of the Formula 2 in the specification and an acetylating agent; and separating the optically active 1-palmitoyl-3-acetylglycerol by crystallizing the reaction mixture in a saturated hydrocarbon solvent having 5 to 7 carbon atoms.

Abstract: The use of at least one compound of formula I or II or pharmaceutically acceptable salts thereof, for preparing a pharmaceutical composition that acts by inhibiting the phosphorylase uridine enzyme, and the use of the compounds for preparing a pharmaceutical composition that acts by inhibiting the human phosphorylase uridine enzyme, which can be optionally used in combination with at least one antineoplastic, wherein the inhibition increases the effectiveness of antineoplastic and decreases the side effects caused by the administration of antineoplastics.

Abstract: The present invention provides a liquid antiseptic composition including (A) parahydroxybenzoic acid ester and (B) water-miscible organic solvent, wherein the (A) parahydroxybenzoic acid ester are two or more esters selected from the group consisting of methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, isopropyl parahydroxybenzoate, butyl parahydroxybenzoate, isobutyl parahydroxybenzoate and benzyl parahydroxybenzoate; the (B) water-miscible organic solvent contains (B-1) at least one organic solvent selected from the group consisting of propylene glycol, butylene glycol, ethanol and polyethylene glycol, and (B-2) 2-phenoxyethanol; and a weight ratio of (A) and (B) is 1:1 to 1:3, and a weight ratio of (B-1) and (B-2) is 1:1 to 1:3.

Abstract: The invention relates to the use of a substance of the general form (I) to produce an antibacterial and/or antifungal drug, wherein X is a methylene group or a carbonyl group; R1, R2, and R3 are each selected from the group comprising hydrogen, an alkyl group having a chain length of 1-4 carbon atoms, an alkoxy group having a chain length of 1-3 carbon atoms, and a halogen; R4 and R5 are each selected from the group comprising hydrogen and an alkyl group having a chain length of 1-4 carbon atoms; and n=3 to 6.